Prevalence of antibodies against rubella virus in the Netherlands 9 years after changing from selective to mass vaccination

Epidemiology and Infection

Volumn 123, Issue 2, 1999, Pages 263-270

  De Haas, R ^a   Van Den Hof, S ^a   Berbers, G A M ^a   De Melker, H E ^a   Conyn Van Spaendonck, M A E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; CONGENITAL RUBELLA SYNDROME; FEMALE; HEALTH CARE POLICY; HUMAN; IMMUNITY; MALE; NETHERLANDS; NORMAL HUMAN; RELIGIOUS GROUP; RISK; RUBELLA; RUBELLA VIRUS; SEROPREVALENCE; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MIDDLE AGED; NETHERLANDS; RUBELLA VIRUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 0032710479     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268899002939     Document Type: Article

References (28)

1. Druten JAM van, Boo Th de, Plantinga AD. Measles, mumps and rubella: control by vaccination. Develop Biol Standard 1986; 65: 53-63.
2. Boo Th de, Druten JAM van, Plantinga AD. Predicting the dynamic effects of rubella vaccination programmes. Stat Med 1987; 6: 843-51.
3. Anonymous. Vaccinatietoestand Nederland per 1 januari 1996. Inspectie van de Gezondheidszorg. Rijswijk, 1997.
4. Hof S van den, Conyn-van Spaendonck MAE, Melker HE de, et al. The effects of vaccination, the incidence of the target diseases. RIVM Report No 213676008, National Institute of Public Health and the Environment. Bilthoven, 1998.
5. Horstmann DM, Schluederberg A, Emmons J, Evans BK, Radolp MF, Andiman WA. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1995; 7: S80-5.
6. Aboudy Y, Fogel A, Barnea B, et al. Subclinical rubella reinfection during pregnancy followed by transmission of virus to the fetus. J Infect 1997; 34: 273-6.
7. Christenson B, Böttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12: 41-5.
8. Hof van den S, Melker HE de, Suijkerbuijk AWM, Conyn-van Spaendonck MAE. Pienter Project: description of serum bank and information on participants from the questionnaires. RIVM Report No 213675005, National Institute of Public Health and the Environment. Bilthoven, 1997.
9. Melker HE de, Conyn-van Spaendonck MAE, Immunosurveillance and the evaluation of national immunisation programmes: a population-based approach. Epidemiol Infect. In press.
10. Harmsen T, Jongerius MC, Zwan CW van der, Plantinga AD, Kraaijeveld CA, Berbers GAM. Comparison of neutralisation enzyme immunoassay and enzyme-linked immunosorbent assay for evaluation of the immune status of mumps vaccinated children. J Clin Microbiol. 1992; 30: 2139-44.
11. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996; 106: 170-4.
12. Cradock-Watson JE, Ridehalg MKS, Anderson MJ, Pattison JR. Outcome of asymptomatic infection with rubella virus during pregnancy. J Hyg 1981; 87: 147-54.
13. Harcourt GC, Best JM, Banatvala JE. Rubella specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after nasal challenge. J Infect Dis 1980; 142: 145-55.
14. Robinson J, Lemay M, Vaudry WL. Congenital rubella after anticipated maternal immunity: two cases and a review of the literature. Pediatr Infect Dis 1994; 13: 812-5.
15. Horstmann DM, Liebhaber H, LeBouvier GL, Rosenberg MDA, Halstead SB. Rubella reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283: 771-8.
16. Best JM, Banatvala JE, Morgan-Capner P, Miller E. Fetal infection after maternal reinfection with rubella: criteria defining reinfection. BMJ 1989; 299: 773-5.
17. Forsgren M, Carlstrom G, Strannegard K. Congenital rubella after maternal reinfection. Scand J Infect Dis 1979; 11: 81-3.
18. Bott LM, Eizenberg DH. Congenital rubella after successful vacination. Med J Aust 1982; 1: 514-5.
19. Mellinger AK, Cragan JD, Atkinson W. et al. High incidence of congenital rubella syndrome after a rubella outbreak. Pediatr Infect Dis J 1995; 14: 573-8.
20. Forsgren M, Sören L. Subclinical rubella reinfection in vaccinated women with rubella specific IgM response during pregnancy and transmission of virus to the fetus. Scand J Infect Dis 1985; 17: 337-41.
21. Ukonnen P, Bonsdorff CH von. Rubella immunity and morbidity: effects of vaccination in Finland. Scand J Infect Dis 1988; 20: 255-9.
22. Matter L, Germann D, Bally F, Schopfer K. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur J Epidemiol 1997; 13: 61-6.
23. Böttiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine 1995; 13: 1759-62.
24. Asahi T, Ueda K, Hidaka Y, Miyazaki C, Tanaka Y, Nishima S. Twenty-three year follow-up study of rubella antibodies after immunization in a closed population, and serological response to revaccination. Vaccine 1997; 16: 1791-5.
25. Enders G. Nickerl U. Rotelimpfung: Antikörperpersistenz für 14-17 jahre und immunstatus von frauen ohne und mit impfanamnese. Immun Infekt 1988; 16: 58-64.
26. Peltola H, Heinonen O, Valle M, et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year two-dose vaccination program. N Engl J Med 1994; 331: 1397-401.
27. Christenson B, Böttiger M. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 1991; 9: 326-9.
28. Heijden OG van der, Conyn-van Spaendonck MAE, Plantinga AD, Kretzschmar MEE. A model-based evaluation of the national immunisation programme against rubella-infection and congenital rubella syndrome in the Netherlands. Epidemiol Infect 1998; 121: 653-71.